跳至主要内容
临床试验/NCT02636127
NCT02636127已完成不适用

Role of Circulating Cytotoxic Lymphocytes in Endothelial Cell Injury in Systemic Sclerosis

Assistance Publique Hopitaux De Marseille1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2015年12月7日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
30
试验地点
1
主要终点
blood sample will be done for dosage of Fractalkine in the serum

研究概览

简要总结

Systemic Sclerosis (SSc) is an auto-immune systemic disease characterized by vascular damage, cutaneous and visceral fibrosis and a dysimmune condition.

Therapies in this disease remain insufficient and the complications resulting from organs involvement lead to strong morbi-mortality.The dermic infiltrate of the patients includes a strong proportion of Tcells. T cells and Natural Killer (NK) cells are potentially involved in the vascular damage of the SSc. However mechanisms at the onset of this endothelial cytotoxicity and its impact on the capacities of regeneration of the endothelial tissue remain poorly understood. Fractalkine is at the same time an endothelial membrane-bound adhesion molecule and a chemokine which is able to bind CX3CR1 expressed by the immune populations. The purpose of the project is to define the role displayed by cytotoxic, circulating immune populations of SSc patients in endothelial cytotoxicity as well as the role of the axis Fractalkine / CX3CR1 in mediating the interactions between the immune cytotoxic cells and the endothelium.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •patients affected by SSc of more than 18 years
  • •Healthy patients

排除标准

  • •Impossibility to take some blood
  • •Current infection
  • •Ongoing cancer
  • •chemotherapy or a current radiotherapy
  • •pregnant or breast-feeding women

研究组 & 干预措施

Systemic Sclerosis (SSc) patient

Experimental

15 patients whose diagnosis of SSc is made according to the revised ACR/EULAR ( American College of Rheumatology ) criteria 2013 will be recruited and blood samples will be obtained

干预措施: blood samples (Other)

healthy patient

Other

15 healthy patients will be recruited and blood samples will be obtained

干预措施: blood samples (Other)

结局指标

主要结局

blood sample will be done for dosage of Fractalkine in the serum

时间窗: 12 months

次要结局

  • blood sample for functional study of the interactions between T cells and NK cells and / endothelial cells (HMVEC)(12 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验